- Home
- ZNB vs PLYX Comparison
ZNB vs PLYX Comparison
Compare ZNB & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNB | PLYX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | |
| Employees | 14 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 114.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNB | PLYX |
|---|---|---|
| Price | $0.22 | $3.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 5.1M |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $2.20 |
| 52 Week High | N/A | $48.91 |
Technical Indicators
Market Signals| Indicator | ZNB | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 30.39 | 27.84 |
| Support Level | $0.21 | $2.20 |
| Resistance Level | $0.29 | $5.00 |
| Average True Range (ATR) | 0.14 | 1.50 |
| MACD | -0.05 | -0.32 |
| Stochastic Oscillator | 1.41 | 26.35 |
Price Performance
Historical ComparisonAbout ZNB Zeta Network Group Class A Ordinary Shares
Zeta Network Group is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.